Innovations + Investments in Healthcare Summit 2015


GenzymeOne of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with approximately 10,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

With many established products and services helping patients in 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and immune disease. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at

Genzyme RSS Channel

Title Filter      Display #  
# Article Title
1 Genzyme recognizes World MS Day
2 Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
3 Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration
4 Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
5 Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
6 Genzyme Revenues Grow in First-Quarter 2011
7 Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
8 Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
9 Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
10 Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year
11 Genzyme Will Allow sanofi-aventis to Conduct Due Diligence
12 Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®
13 Genzyme Financial Recovery Continues in Fourth Quarter
14 Genzyme Statement on Discussions With Sanofi-Aventis
15 Genzyme Details Market Potential of Alemtuzumab for MS
16 Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer
17 Genzyme Completes Sale of Genetic Testing Business to LabCorp
18 Genzyme Announces Agreement to Sell Diagnostics Business
19 Genzyme Responds to Sanofi-Aventis Letter
20 Genzyme Reports Financial Results for the Third Quarter of 2010
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]